Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04276376
Title Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES)
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Gustave Roussy, Cancer Campus, Grand Paris
Indications
Therapies
Age Groups: senior | adult
Covered Countries FRA

Additional content available in CKB BOOST